Kadmon Holdings, Inc.
(NASDAQ : KDMN)

( )
KDMN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -2.45%98.560.0%$1438.14m
BIIBBiogen, Inc. -0.36%242.511.7%$630.38m
AMGNAmgen, Inc. -0.79%220.461.3%$568.17m
GILDGilead Sciences, Inc. 0.60%60.251.0%$535.76m
VRTXVertex Pharmaceuticals, Inc. -0.63%216.501.9%$470.81m
REGNRegeneron Pharmaceuticals, Inc. -3.34%506.102.7%$447.76m
BNTXBioNTech SE -4.35%101.870.0%$424.45m
ILMNIllumina, Inc. 1.25%305.633.5%$377.98m
NVAXNovavax, Inc. 1.44%95.3392.9%$339.05m
EXASEXACT Sciences Corp. -2.72%117.2619.6%$289.27m
MGENMiragen Therapeutics, Inc. -4.62%16.500.7%$248.55m
SRRKScholar Rock Holding Corp. 3.14%42.700.0%$242.63m
APVOAptevo Therapeutics, Inc. -3.58%43.9218.3%$210.20m
SGENSeagen Inc. -2.05%164.635.8%$167.34m
ALXNAlexion Pharmaceuticals, Inc. 0.41%123.112.0%$161.56m

Company Profile

Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.